David Einhorn
Greenlight Capital
David Einhorn Talis Biomedical Corp stake
total: 357
Greenlight Capital TLIS trades
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2021 Q4
- Held for:
- 11 quarters
- Latest activity:
- 2024 Q3
According to 2026 Q2 report, David Einhorn doesn't hold any Talis Biomedical Corp (TLIS) shares. To date, the estimated cost basis is nearly $48.52 for "buy" trades and estimated average "sell" price is $8.66. Greenlight Capital first purchased TLIS in 2021 Q4, initially acquiring 104,620 shares. Since the initial investment in Talis Biomedical Corp (TLIS), Greenlight Capital has made 3 more transactions.
When did David Einhorn sell Talis Biomedical Corp (TLIS)?
David Einhorn sold off the entire Talis Biomedical Corp (TLIS) position in 2024 Q3.
When did David Einhorn buy Talis Biomedical Corp (TLIS)?
David Einhorn first invested in Talis Biomedical Corp (TLIS) in 2021 Q4 at the reported quarter-end price of $60.15 per share.
What's the cost basis of Greenlight Capital's TLIS stake?
The estimated cost basis for Talis Biomedical Corp (TLIS) stake is around $48.52 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $48.52
- Weighted AVG sell price:
- $8.66
David Einhorn's historical trades in Talis Biomedical Corp
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q3
|
0.00%
|
0
|
$8.66
|
|
-100% (-149,052)
|
-0.06%
|
|
2023 Q3
|
0.05%
|
149,052
|
$5.77
|
$860,030
|
-0.00% (-0.2)
|
0%
|
|
2022 Q1
|
0.20%
|
149,052.2
|
$21.15
|
$3,152,000
|
+42.47% (+44,432.2)
|
+0.06%
|
|
2021 Q4
|
0.38%
|
104,620
|
$60.15
|
$6,293,000
|
new
|
+0.38%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.